董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Elizabeth G. Trehu | 女 | Director | 60 | 39.13万美元 | 未持股 | 2021-04-01 |
| Jigar Raythatha | 男 | Director, President and Chief Executive Officer | 44 | 586.26万美元 | 未持股 | 2021-04-01 |
| James E. Audia | 男 | Director | 65 | 40.46万美元 | 未持股 | 2021-04-01 |
| Mark A. Goldsmith | 男 | Director | 59 | 43.28万美元 | 未持股 | 2021-04-01 |
| Scott N. Braunstein | 男 | Director | 57 | 40.03万美元 | 未持股 | 2021-04-01 |
| Richard S. Levy | 男 | Director | 63 | 58.67万美元 | 未持股 | 2021-04-01 |
| Steven L. Hoerter | 男 | Director | 50 | 40.08万美元 | 未持股 | 2021-04-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Emma Reeve | 女 | Treasurer, Senior Vice President and Chief Financial Officer | 60 | 208.16万美元 | 未持股 | 2021-04-01 |
| Jigar Raythatha | 男 | Director, President and Chief Executive Officer | 44 | 586.26万美元 | 未持股 | 2021-04-01 |
| Patrick Trojer | 男 | Chief Scientific Officer | 48 | 194.85万美元 | 未持股 | 2021-04-01 |
| Jeffrey Humphrey | 男 | Chief Medical Officer | 59 | 317.05万美元 | 未持股 | 2021-04-01 |
| Karen Valentine | 女 | Chief Legal Officer and General Counsel | 49 | 159.39万美元 | 未持股 | 2021-04-01 |
董事简历
中英对照 | 中文 | 英文- Elizabeth G. Trehu
-
Elizabeth G. Trehu，2015年11月，Trehu加入Jounce，出任Jounce Therapeutics，Inc.股份有限公司首席医疗官。在加入Jounce之前，Trehu博士于2012年至2015年11月担任生物技术公司Promedior，Inc.的首席医疗官。Trehu博士拥有纽约大学医学院的医学博士学位和普林斯顿大学的英语学士学位。
Elizabeth G. Trehu,M.D. —Dr. Trehu joined Jounce as Jounce Therapeutics, Inc. chief medical officer in November 2015. Prior to joining Jounce, Dr. Trehu served as the chief medical officer of Promedior, Inc., a biotechnology company, from 2012 to November 2015. Dr. Trehu holds an M.D. from the New York University School of Medicine and an A.B. in English from Princeton University. - Elizabeth G. Trehu，2015年11月，Trehu加入Jounce，出任Jounce Therapeutics，Inc.股份有限公司首席医疗官。在加入Jounce之前，Trehu博士于2012年至2015年11月担任生物技术公司Promedior，Inc.的首席医疗官。Trehu博士拥有纽约大学医学院的医学博士学位和普林斯顿大学的英语学士学位。
- Elizabeth G. Trehu,M.D. —Dr. Trehu joined Jounce as Jounce Therapeutics, Inc. chief medical officer in November 2015. Prior to joining Jounce, Dr. Trehu served as the chief medical officer of Promedior, Inc., a biotechnology company, from 2012 to November 2015. Dr. Trehu holds an M.D. from the New York University School of Medicine and an A.B. in English from Princeton University.
- Jigar Raythatha
-
Jigar Raythatha自2017年3月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。Raythatha先生曾于2012年12月至2017年2月担任生物技术公司JounceTherapeutics，Inc.的首席商务官，在那里他帮助将公司从成立之初建立为公开交易的研究与开发组织。此前，他曾担任我们的公司发展主管（从2009年3月到2013年2月），在那里他曾领导业务发展、战略、计划和联盟管理职能。在担任公司发展主管之前，Raythatha先生于2005年加入Red Abbey Venture Partners，LLC，并于2005年至2007年担任考夫曼研究员，于2007年至2009年担任负责人，并于2009年担任风险合伙人。加入Red Abbey Venture Partners之前，Raythatha从1999年到2003年在BiogenInc.担任多个业务开发、商业和项目管理职位。他在哥伦比亚大学（Columbia University）获得工商管理硕士学位，在罗格斯大学（Rutgers University）获得生物化学和经济学学士学位。
Jigar Raythatha has served as our President and Chief Executive Officer and as a member of our Board of Directors since March 2017. Mr. Raythatha previously served as Chief Business Officer of Jounce Therapeutics, Inc., a biotechnology company, from December 2012 to February 2017 where he helped build the company from its inception to a publicly traded research and development organization. Previously, he served as our Head of Corporate Development from March 2009 to February 2013 where he led business development, strategy and program and alliance management functions. Prior to serving as our Head of Corporate Development, Mr. Raythatha joined Red Abbey Venture Partners, LLC in 2005 and served as a Kauffman Fellow from 2005 to 2007 principal from 2007 to 2009 and venture partner in 2009. Prior to Red Abbey Venture Partners, Mr. Raythatha worked at Biogen Inc. from 1999 to 2003 in a variety of business development, commercial, and program management roles. He earned an M.B.A. from Columbia University and a B.A. in biochemistry and economics from Rutgers University. - Jigar Raythatha自2017年3月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。Raythatha先生曾于2012年12月至2017年2月担任生物技术公司JounceTherapeutics，Inc.的首席商务官，在那里他帮助将公司从成立之初建立为公开交易的研究与开发组织。此前，他曾担任我们的公司发展主管（从2009年3月到2013年2月），在那里他曾领导业务发展、战略、计划和联盟管理职能。在担任公司发展主管之前，Raythatha先生于2005年加入Red Abbey Venture Partners，LLC，并于2005年至2007年担任考夫曼研究员，于2007年至2009年担任负责人，并于2009年担任风险合伙人。加入Red Abbey Venture Partners之前，Raythatha从1999年到2003年在BiogenInc.担任多个业务开发、商业和项目管理职位。他在哥伦比亚大学（Columbia University）获得工商管理硕士学位，在罗格斯大学（Rutgers University）获得生物化学和经济学学士学位。
- Jigar Raythatha has served as our President and Chief Executive Officer and as a member of our Board of Directors since March 2017. Mr. Raythatha previously served as Chief Business Officer of Jounce Therapeutics, Inc., a biotechnology company, from December 2012 to February 2017 where he helped build the company from its inception to a publicly traded research and development organization. Previously, he served as our Head of Corporate Development from March 2009 to February 2013 where he led business development, strategy and program and alliance management functions. Prior to serving as our Head of Corporate Development, Mr. Raythatha joined Red Abbey Venture Partners, LLC in 2005 and served as a Kauffman Fellow from 2005 to 2007 principal from 2007 to 2009 and venture partner in 2009. Prior to Red Abbey Venture Partners, Mr. Raythatha worked at Biogen Inc. from 1999 to 2003 in a variety of business development, commercial, and program management roles. He earned an M.B.A. from Columbia University and a B.A. in biochemistry and economics from Rutgers University.
- James E. Audia
-
JamesE.Audia自2017年7月以来一直担任我们的董事会成员。Audia博士目前担任芝加哥生物医学联盟（CBC）的执行董事，该联盟是西北大学（Northwestern University），芝加哥大学（University of Chicago）和伊利诺伊大学芝加哥分校（University of Illinois-Chicago）的合作项目，专注于加强生物医学创新。在2017年8月加入CBC之前，Audia博士于2011年1月至2017年7月担任我们的首席科学官。在加入我们担任首席科学官之前，Audia博士从1987年到2010年12月在Eli Lilly&Company（一家全球梦百合公司）担任多个职位。2011年1月至2017年12月，Audia博士担任上市生物制药公司SageTherapeutics，Inc.的科学顾问。Audia博士还担任Ribon Therapeutics，Inc.的科学顾问和董事会成员，该公司是一家私人生物技术公司。他在南卡罗来纳大学（University of South Carolina）获得有机化学B.S.和博士学位，并在耶鲁大学（Yale University）完成博士后培训。
James E. Audia has served as a member of our Board of Directors since July 2017. Dr. Audia is the President and Sole Proprietor of Audia Consulting, LLC, a scientific consulting firm which he founded in September 2019. Since November 2019 he has also served as an entrepreneur in residence for Third Rock Ventures, a venture capital firm. Since November 2019 he has also been Senior Advisor and Head of Chemistry for Karuna Therapeutics, Inc., a publicly traded biopharmaceutical company. Dr Audia has been on the scientific advisory board of the Alzheimer’s Association since January 2020. Between August 2017 and October 2019 Dr. Audia served as Executive Director of the Chicago Biomedical Consortium “CBC”, a collaborative effort of Northwestern University, The University of Chicago and The University of Illinois-Chicago, focused on enhancing biomedical innovation. Prior to joining the CBC, Dr. Audia served as our Chief Scientific Officer from January 2011 to July 2017. Prior to joining us as Chief Scientific Officer, Dr. Audia served in a number of roles at Eli Lilly & Company, a global healthcare company, from 1987 until December 2010. From January 2011 to December 2017 Dr. Audia served as a scientific advisor to Sage Therapeutics, Inc., a public biopharmaceutical company. He received a B.S. and Ph.D. in organic chemistry from the University of South Carolina and completed postdoctoral training at Yale University. - JamesE.Audia自2017年7月以来一直担任我们的董事会成员。Audia博士目前担任芝加哥生物医学联盟（CBC）的执行董事，该联盟是西北大学（Northwestern University），芝加哥大学（University of Chicago）和伊利诺伊大学芝加哥分校（University of Illinois-Chicago）的合作项目，专注于加强生物医学创新。在2017年8月加入CBC之前，Audia博士于2011年1月至2017年7月担任我们的首席科学官。在加入我们担任首席科学官之前，Audia博士从1987年到2010年12月在Eli Lilly&Company（一家全球梦百合公司）担任多个职位。2011年1月至2017年12月，Audia博士担任上市生物制药公司SageTherapeutics，Inc.的科学顾问。Audia博士还担任Ribon Therapeutics，Inc.的科学顾问和董事会成员，该公司是一家私人生物技术公司。他在南卡罗来纳大学（University of South Carolina）获得有机化学B.S.和博士学位，并在耶鲁大学（Yale University）完成博士后培训。
- James E. Audia has served as a member of our Board of Directors since July 2017. Dr. Audia is the President and Sole Proprietor of Audia Consulting, LLC, a scientific consulting firm which he founded in September 2019. Since November 2019 he has also served as an entrepreneur in residence for Third Rock Ventures, a venture capital firm. Since November 2019 he has also been Senior Advisor and Head of Chemistry for Karuna Therapeutics, Inc., a publicly traded biopharmaceutical company. Dr Audia has been on the scientific advisory board of the Alzheimer’s Association since January 2020. Between August 2017 and October 2019 Dr. Audia served as Executive Director of the Chicago Biomedical Consortium “CBC”, a collaborative effort of Northwestern University, The University of Chicago and The University of Illinois-Chicago, focused on enhancing biomedical innovation. Prior to joining the CBC, Dr. Audia served as our Chief Scientific Officer from January 2011 to July 2017. Prior to joining us as Chief Scientific Officer, Dr. Audia served in a number of roles at Eli Lilly & Company, a global healthcare company, from 1987 until December 2010. From January 2011 to December 2017 Dr. Audia served as a scientific advisor to Sage Therapeutics, Inc., a public biopharmaceutical company. He received a B.S. and Ph.D. in organic chemistry from the University of South Carolina and completed postdoctoral training at Yale University.
- Mark A. Goldsmith
-
MarkA.Goldsmith自2014年11月以来一直担任我们的董事会成员以及总裁兼首席执行官。自2009年以来，戈德史密斯博士一直担任生物制药公司ConstellationPharmaceuticals，Inc.的董事会成员，2009年至2012年，他还担任该公司的总裁兼首席执行官，2012年至2016年6月，以及2017年3月至今，担任董事长，以及于2016年6月至2017年3月担任临时执行主席。Goldsmith博士此前曾于2013年至2015年担任生命科学风险投资公司Third Rock Ventures的合伙人，并于2012年至2013年担任Third Rock的风险合伙人。Goldsmith从2012年到2014年担任Global Blood Therapeutics（一家生物制药公司）总裁和首席执行官以及董事会成员。Goldsmith博士还于2012年至2014年担任药物发现公司Nurix，Inc.的总裁兼首席执行官。在进入私营部门之前，Goldsmith博士领导了Gladstone病毒学和免疫学研究所的医学研究实验室，在加州大学旧金山分校医学院和旧金山总医院的院系行医，并曾是领先的制药和生物技术公司的顾问。Goldsmith博士在普林斯顿大学（Princeton University）获得生物学学士学位，并在加州大学旧金山分校（University of California，San Francisco）医学院获得微生物学和免疫学硕士学位和博士学位。
Mark A. Goldsmith has served as a member of our Board of Directors since July 2009. Dr. Goldsmith has been the President and Chief Executive Officer and a director of Revolution Medicines, Inc., a publicly traded drug discovery and development company, since November 2014. Dr. Goldsmith was previously a partner with Third Rock Ventures, L.P. “Third Rock”, a venture capital firm, from March 2012 until 2015 and a venture partner with Third Rock from 2015 until March 2018. Dr. Goldsmith previously served as our President and Chief Executive Officer from June 2009 to March 2012 and as our Interim Executive Chairman from June 2016 to March 2017. Dr. Goldsmith served as President and Chief Executive Officer of Global Blood Therapeutics, a biotechnology company, from May 2012 to June 2014 and on its board of directors from May 2012 to September 2014. Dr. Goldsmith also served as President and Chief Executive Officer of Nurix, Inc., a drug discovery company, from May 2012 to October 2014. Before entering the private sector, Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the School of Medicine of the University of California, San Francisco and the San Francisco General Hospital, and was a consultant to leading pharmaceutical and biotechnology companies. Dr. Goldsmith holds an A.B. from Princeton University and a M.D. and Ph.D. in microbiology and immunology from the University of California, San Francisco. - MarkA.Goldsmith自2014年11月以来一直担任我们的董事会成员以及总裁兼首席执行官。自2009年以来，戈德史密斯博士一直担任生物制药公司ConstellationPharmaceuticals，Inc.的董事会成员，2009年至2012年，他还担任该公司的总裁兼首席执行官，2012年至2016年6月，以及2017年3月至今，担任董事长，以及于2016年6月至2017年3月担任临时执行主席。Goldsmith博士此前曾于2013年至2015年担任生命科学风险投资公司Third Rock Ventures的合伙人，并于2012年至2013年担任Third Rock的风险合伙人。Goldsmith从2012年到2014年担任Global Blood Therapeutics（一家生物制药公司）总裁和首席执行官以及董事会成员。Goldsmith博士还于2012年至2014年担任药物发现公司Nurix，Inc.的总裁兼首席执行官。在进入私营部门之前，Goldsmith博士领导了Gladstone病毒学和免疫学研究所的医学研究实验室，在加州大学旧金山分校医学院和旧金山总医院的院系行医，并曾是领先的制药和生物技术公司的顾问。Goldsmith博士在普林斯顿大学（Princeton University）获得生物学学士学位，并在加州大学旧金山分校（University of California，San Francisco）医学院获得微生物学和免疫学硕士学位和博士学位。
- Mark A. Goldsmith has served as a member of our Board of Directors since July 2009. Dr. Goldsmith has been the President and Chief Executive Officer and a director of Revolution Medicines, Inc., a publicly traded drug discovery and development company, since November 2014. Dr. Goldsmith was previously a partner with Third Rock Ventures, L.P. “Third Rock”, a venture capital firm, from March 2012 until 2015 and a venture partner with Third Rock from 2015 until March 2018. Dr. Goldsmith previously served as our President and Chief Executive Officer from June 2009 to March 2012 and as our Interim Executive Chairman from June 2016 to March 2017. Dr. Goldsmith served as President and Chief Executive Officer of Global Blood Therapeutics, a biotechnology company, from May 2012 to June 2014 and on its board of directors from May 2012 to September 2014. Dr. Goldsmith also served as President and Chief Executive Officer of Nurix, Inc., a drug discovery company, from May 2012 to October 2014. Before entering the private sector, Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the School of Medicine of the University of California, San Francisco and the San Francisco General Hospital, and was a consultant to leading pharmaceutical and biotechnology companies. Dr. Goldsmith holds an A.B. from Princeton University and a M.D. and Ph.D. in microbiology and immunology from the University of California, San Francisco.
- Scott N. Braunstein
-
Scott N.Braunstein自2019年2月以来一直担任我们的董事会成员。自2019年8月以来，Braunstein博士一直担任上市生物制药公司Marinus Pharmaceuticals的首席执行官。自2015年9月起，Braunstein博士还担任Aisling Capital的运营合伙人。2015年7月至2018年3月，Braunstein博士在特种制药公司Pacira Pharmaceuticals，Inc.担任首席运营官，公司战略高级副总裁兼首席战略官。Braunstein博士于2002年至2014年担任J.P.Morgan Asset Management（一家投资公司）的医疗保健投资组合经理，并于2014年至2015年担任Everpoint Asset Management。Braunstein博士是摩根大通资产管理公司（J.P.Morgan Asset Management）的医疗保健分析师和董事总经理，也是摩根大通全球医疗保健基金（J.P.Morgan Global Asset Fund）的投资组合经理。Braunstein博士目前在以下上市公司的董事会任职:MarinusPharmaceuticals，Inc.和Trevena，Inc.，Braunstein博士此前在以下上市公司的董事会任职:EsperionTherapeutics，Inc.直到2020年4月Ziopharm Oncology，Inc.直到2020年11月，Protara Therapeutics，Inc.以前称为ArTaraTherapeutics，Inc.，直到2020年7月。他获得了康奈尔大学的应用科学学士学位和阿尔伯特爱因斯坦医学院的医学博士学位。
Scott N. Braunstein has served as a member of our Board of Directors since February 2019. Dr. Braunstein has served as the Chief Executive Officer of Marinus Pharmaceuticals, a publicly traded biopharmaceutical company, since August 2019. Dr. Braunstein also serves as an Operating Partner at Aisling Capital since September 2015. From July 2015 to March 2018 Dr. Braunstein served as Chief Operating Officer, SVP of Corporate Strategy and Chief Strategy Officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company. Dr. Braunstein served as a healthcare portfolio manager at J.P. Morgan Asset Management, an investment firm from 2002 to 2014 and Everpoint Asset Management from 2014 to 2015. Dr. Braunstein was a healthcare analyst and managing director at J.P. Morgan Asset Management and portfolio manager for the J.P. Morgan Global Healthcare fund. Dr. Braunstein currently serves on the board of directors of the following public companies: Marinus Pharmaceuticals, Inc. and Trevena, Inc., and Dr. Braunstein previously served on the board of directors of the following public companies: Esperion Therapeutics, Inc. until April 2020 Ziopharm Oncology, Inc. until November 2020 and Protara Therapeutics, Inc. formerly known as ArTara Therapeutics, Inc. until July 2020. He earned his Bachelor of Applied Science from Cornell University and his M.D. from the Albert Einstein College of Medicine. - Scott N.Braunstein自2019年2月以来一直担任我们的董事会成员。自2019年8月以来，Braunstein博士一直担任上市生物制药公司Marinus Pharmaceuticals的首席执行官。自2015年9月起，Braunstein博士还担任Aisling Capital的运营合伙人。2015年7月至2018年3月，Braunstein博士在特种制药公司Pacira Pharmaceuticals，Inc.担任首席运营官，公司战略高级副总裁兼首席战略官。Braunstein博士于2002年至2014年担任J.P.Morgan Asset Management（一家投资公司）的医疗保健投资组合经理，并于2014年至2015年担任Everpoint Asset Management。Braunstein博士是摩根大通资产管理公司（J.P.Morgan Asset Management）的医疗保健分析师和董事总经理，也是摩根大通全球医疗保健基金（J.P.Morgan Global Asset Fund）的投资组合经理。Braunstein博士目前在以下上市公司的董事会任职:MarinusPharmaceuticals，Inc.和Trevena，Inc.，Braunstein博士此前在以下上市公司的董事会任职:EsperionTherapeutics，Inc.直到2020年4月Ziopharm Oncology，Inc.直到2020年11月，Protara Therapeutics，Inc.以前称为ArTaraTherapeutics，Inc.，直到2020年7月。他获得了康奈尔大学的应用科学学士学位和阿尔伯特爱因斯坦医学院的医学博士学位。
- Scott N. Braunstein has served as a member of our Board of Directors since February 2019. Dr. Braunstein has served as the Chief Executive Officer of Marinus Pharmaceuticals, a publicly traded biopharmaceutical company, since August 2019. Dr. Braunstein also serves as an Operating Partner at Aisling Capital since September 2015. From July 2015 to March 2018 Dr. Braunstein served as Chief Operating Officer, SVP of Corporate Strategy and Chief Strategy Officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company. Dr. Braunstein served as a healthcare portfolio manager at J.P. Morgan Asset Management, an investment firm from 2002 to 2014 and Everpoint Asset Management from 2014 to 2015. Dr. Braunstein was a healthcare analyst and managing director at J.P. Morgan Asset Management and portfolio manager for the J.P. Morgan Global Healthcare fund. Dr. Braunstein currently serves on the board of directors of the following public companies: Marinus Pharmaceuticals, Inc. and Trevena, Inc., and Dr. Braunstein previously served on the board of directors of the following public companies: Esperion Therapeutics, Inc. until April 2020 Ziopharm Oncology, Inc. until November 2020 and Protara Therapeutics, Inc. formerly known as ArTara Therapeutics, Inc. until July 2020. He earned his Bachelor of Applied Science from Cornell University and his M.D. from the Albert Einstein College of Medicine.
- Richard S. Levy
-
2003年8月，Richard S. Levy加入公司，并担任药物开发的高级副总裁；2009年1月，开始担任执行副总裁兼首席药物开发和医疗官。加入Incyte之前，从2002年到2003年，他在 Celgene Corporation担任药物开发职位，负责临床研究和监管事务；从1997年到2002年，在 DuPont Pharmaceuticals Company任职；从1991年到1997年，在 Sandoz任职， Sandoz现在是Novartis的一部分。加入制药行业之前，他是加州大学洛杉矶分校医学院的医学助理教授。他是内科医学胃肠病学委员会成员，取得了布朗大学文科学士和宾夕法尼亚大学医学博士学位。
Richard S. Levy,has served on Board of Directors since March 2019. Dr. Levy served as a Senior Advisor at Baker Bros. Advisors LP ("Baker Brothers Advisors") from December 2016 to May 2019. Prior to that, Dr. Levy served as Executive Vice President and Chief Drug Development Officer at Incyte Corporation, a biopharmaceutical company, from January 2009 until June 2016, and as Senior Vice President of Drug Development from August 2003 to January 2009. Dr. Levy currently serves on the boards of directors of Madrigal Pharmaceuticals, Inc., Protara Therapeutics, Inc. (f/k/a ArTara Therapeutics, Inc.) and Kodiak Sciences, and previously served on the board of directors of Constellation Pharmaceuticals, Inc. and Aquinox Pharmaceuticals, Inc. Dr. Levy is Board Certified in Internal Medicine and Gastroenterology and holds an A.B. in Biology from Brown University and an M.D. from the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA. - 2003年8月，Richard S. Levy加入公司，并担任药物开发的高级副总裁；2009年1月，开始担任执行副总裁兼首席药物开发和医疗官。加入Incyte之前，从2002年到2003年，他在 Celgene Corporation担任药物开发职位，负责临床研究和监管事务；从1997年到2002年，在 DuPont Pharmaceuticals Company任职；从1991年到1997年，在 Sandoz任职， Sandoz现在是Novartis的一部分。加入制药行业之前，他是加州大学洛杉矶分校医学院的医学助理教授。他是内科医学胃肠病学委员会成员，取得了布朗大学文科学士和宾夕法尼亚大学医学博士学位。
- Richard S. Levy,has served on Board of Directors since March 2019. Dr. Levy served as a Senior Advisor at Baker Bros. Advisors LP ("Baker Brothers Advisors") from December 2016 to May 2019. Prior to that, Dr. Levy served as Executive Vice President and Chief Drug Development Officer at Incyte Corporation, a biopharmaceutical company, from January 2009 until June 2016, and as Senior Vice President of Drug Development from August 2003 to January 2009. Dr. Levy currently serves on the boards of directors of Madrigal Pharmaceuticals, Inc., Protara Therapeutics, Inc. (f/k/a ArTara Therapeutics, Inc.) and Kodiak Sciences, and previously served on the board of directors of Constellation Pharmaceuticals, Inc. and Aquinox Pharmaceuticals, Inc. Dr. Levy is Board Certified in Internal Medicine and Gastroenterology and holds an A.B. in Biology from Brown University and an M.D. from the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA.
- Steven L. Hoerter
-
2011年8月以来，Steven L. Hoerter担任商业高级副总裁。从2010年到2011年，他担任Hoffmann-LaRoche总经理及管理中心负责人，负责非洲撒哈拉以南和印度洋地区，位于南非约翰内斯堡。从2005年到2010年，他在Genentech担任多种职位，包括带领高级领导团队，担任Genentech公司的BioOncology业务高级董事，负责管道开发和商业运作。之前，他在喀戎公司和礼来公司任职。他在礼来公司Hoerter任职 11年，他负责美国、欧洲和非洲的销售、业务发展、市场营销和业务单元管理。他拥有巴克内尔大学俄罗斯与政治学学士学位，蒂尔堡大学MBA学位和普渡大学管理学硕士学位。
Steven L. Hoerter has served as a member of our Board of Directors since September 2018. Mr. Hoerter is currently the President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. “Deciphera”, a clinical stage public biopharmaceutical company, a position he has held since March 18 2019. Prior to joining Deciphera, Mr. Hoerter served as the Chief Commercial Officer of Agios Pharmaceuticals, a public biopharmaceutical company, from February 2016 to March 2019. He has more than 20 years of global pharmaceutical and biotechnology experience. Mr. Hoerter served, from August 2011 to February 2016 as Executive Vice President and Chief Commercial Officer at Clovis Oncology, Inc., a public biopharmaceutical company. Before joining Clovis in August 2011 he was General Manager and Management Center Head at Roche Group for the Sub-Saharan Africa and Indian Ocean Region. From 2005 to 2010 Mr. Hoerter held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s bio-oncology business as Senior Director, Pipeline Development and Commercial Operations. Mr. Hoerter serves on the board of directors of Deciphera and served on the board of directors of Ignyta Pharma, a public pharmaceutical company, from December 2016 to February 2018. Prior to that, Mr. Hoerter held commercial roles at Chiron Corporation and Eli Lilly and Company in the United States, Europe and Africa. Mr. Hoerter received his B.A. from Bucknell University, M.B.A. from Tilburg University and M.S. in management from Purdue University. - 2011年8月以来，Steven L. Hoerter担任商业高级副总裁。从2010年到2011年，他担任Hoffmann-LaRoche总经理及管理中心负责人，负责非洲撒哈拉以南和印度洋地区，位于南非约翰内斯堡。从2005年到2010年，他在Genentech担任多种职位，包括带领高级领导团队，担任Genentech公司的BioOncology业务高级董事，负责管道开发和商业运作。之前，他在喀戎公司和礼来公司任职。他在礼来公司Hoerter任职 11年，他负责美国、欧洲和非洲的销售、业务发展、市场营销和业务单元管理。他拥有巴克内尔大学俄罗斯与政治学学士学位，蒂尔堡大学MBA学位和普渡大学管理学硕士学位。
- Steven L. Hoerter has served as a member of our Board of Directors since September 2018. Mr. Hoerter is currently the President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. “Deciphera”, a clinical stage public biopharmaceutical company, a position he has held since March 18 2019. Prior to joining Deciphera, Mr. Hoerter served as the Chief Commercial Officer of Agios Pharmaceuticals, a public biopharmaceutical company, from February 2016 to March 2019. He has more than 20 years of global pharmaceutical and biotechnology experience. Mr. Hoerter served, from August 2011 to February 2016 as Executive Vice President and Chief Commercial Officer at Clovis Oncology, Inc., a public biopharmaceutical company. Before joining Clovis in August 2011 he was General Manager and Management Center Head at Roche Group for the Sub-Saharan Africa and Indian Ocean Region. From 2005 to 2010 Mr. Hoerter held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s bio-oncology business as Senior Director, Pipeline Development and Commercial Operations. Mr. Hoerter serves on the board of directors of Deciphera and served on the board of directors of Ignyta Pharma, a public pharmaceutical company, from December 2016 to February 2018. Prior to that, Mr. Hoerter held commercial roles at Chiron Corporation and Eli Lilly and Company in the United States, Europe and Africa. Mr. Hoerter received his B.A. from Bucknell University, M.B.A. from Tilburg University and M.S. in management from Purdue University.
高管简历
中英对照 | 中文 | 英文- Emma Reeve
Emma Reeve，她一直担任公司的公司副总裁兼临时首席财务官（2016年7月以来）。2014年9月以来，她也曾担任公司的公司总会计师，并负责SEC报告、投资者关系、财务规划和分析、共享服务中心和过程改进。从2012年5月到2014年8月，她担任Novartis Pharma Schweiz（一个制药公司）的财务行政主管。2008年1月至2012年4月，她曾担任Novartis Vaccines and Diagnostics（从属于Novartis）的副总裁，负责全球业务规划和分析。此前，她曾担任一些领导财务职务，包括担任两家生物制药公司的首席财务官，以及Bristol-Myers Squibb和Merck的财务领导职务。她持有伦敦大学帝国科学和技术理工学院（the Imperial College of Science and Technology, University of London）的计算机科学学位。她是注册会计师。
Emma Reeve has served as our Senior Vice President and Chief Financial Officer since October 2017 and as our Treasurer since December 2017. Prior to joining us, Ms. Reeve served as Corporate Controller of PAREXEL International, a biopharmaceutical services company and contract research organization, from September 2014 to October 2017 and as Interim Chief Financial Officer and Corporate Controller of PAREXEL from July 2016 to May 2017 where she was responsible for all aspects of financial reporting and accounting, investor relations, financial planning and analysis. Previously, Ms. Reeve served as Head of Finance and Administration at Novartis Pharma Schweiz, a pharmaceutical company, from May 2012 to August 2014 and as Vice President, Global Head Business Planning and Analysis for Novartis Vaccines and Diagnostics, a division of Novartis, from January 2008 to April 2012. She served as Chief Financial Officer of Inotek Pharmaceuticals Inc., a development-stage biotechnology company, from 2006 to 2007. Ms. Reeve was Senior Director of Research Operations at Merck Research Laboratories from 2004 to 2006. Prior to that she served as Chief Financial Officer of Aton Pharma, Inc., a development-stage biotechnology company, from 2002 to 2004. Ms. Reeve was at Bristol-Myers Squibb Company, a global biopharmaceuticals company, from 1994 to 2002. Ms. Reeve holds a B.Sc. in computer science from Imperial College, University of London and is an associate of the Institute of Chartered Accountants in England & Wales.- Emma Reeve，她一直担任公司的公司副总裁兼临时首席财务官（2016年7月以来）。2014年9月以来，她也曾担任公司的公司总会计师，并负责SEC报告、投资者关系、财务规划和分析、共享服务中心和过程改进。从2012年5月到2014年8月，她担任Novartis Pharma Schweiz（一个制药公司）的财务行政主管。2008年1月至2012年4月，她曾担任Novartis Vaccines and Diagnostics（从属于Novartis）的副总裁，负责全球业务规划和分析。此前，她曾担任一些领导财务职务，包括担任两家生物制药公司的首席财务官，以及Bristol-Myers Squibb和Merck的财务领导职务。她持有伦敦大学帝国科学和技术理工学院（the Imperial College of Science and Technology, University of London）的计算机科学学位。她是注册会计师。
- Emma Reeve has served as our Senior Vice President and Chief Financial Officer since October 2017 and as our Treasurer since December 2017. Prior to joining us, Ms. Reeve served as Corporate Controller of PAREXEL International, a biopharmaceutical services company and contract research organization, from September 2014 to October 2017 and as Interim Chief Financial Officer and Corporate Controller of PAREXEL from July 2016 to May 2017 where she was responsible for all aspects of financial reporting and accounting, investor relations, financial planning and analysis. Previously, Ms. Reeve served as Head of Finance and Administration at Novartis Pharma Schweiz, a pharmaceutical company, from May 2012 to August 2014 and as Vice President, Global Head Business Planning and Analysis for Novartis Vaccines and Diagnostics, a division of Novartis, from January 2008 to April 2012. She served as Chief Financial Officer of Inotek Pharmaceuticals Inc., a development-stage biotechnology company, from 2006 to 2007. Ms. Reeve was Senior Director of Research Operations at Merck Research Laboratories from 2004 to 2006. Prior to that she served as Chief Financial Officer of Aton Pharma, Inc., a development-stage biotechnology company, from 2002 to 2004. Ms. Reeve was at Bristol-Myers Squibb Company, a global biopharmaceuticals company, from 1994 to 2002. Ms. Reeve holds a B.Sc. in computer science from Imperial College, University of London and is an associate of the Institute of Chartered Accountants in England & Wales.
- Jigar Raythatha
Jigar Raythatha自2017年3月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。Raythatha先生曾于2012年12月至2017年2月担任生物技术公司JounceTherapeutics，Inc.的首席商务官，在那里他帮助将公司从成立之初建立为公开交易的研究与开发组织。此前，他曾担任我们的公司发展主管（从2009年3月到2013年2月），在那里他曾领导业务发展、战略、计划和联盟管理职能。在担任公司发展主管之前，Raythatha先生于2005年加入Red Abbey Venture Partners，LLC，并于2005年至2007年担任考夫曼研究员，于2007年至2009年担任负责人，并于2009年担任风险合伙人。加入Red Abbey Venture Partners之前，Raythatha从1999年到2003年在BiogenInc.担任多个业务开发、商业和项目管理职位。他在哥伦比亚大学（Columbia University）获得工商管理硕士学位，在罗格斯大学（Rutgers University）获得生物化学和经济学学士学位。
Jigar Raythatha has served as our President and Chief Executive Officer and as a member of our Board of Directors since March 2017. Mr. Raythatha previously served as Chief Business Officer of Jounce Therapeutics, Inc., a biotechnology company, from December 2012 to February 2017 where he helped build the company from its inception to a publicly traded research and development organization. Previously, he served as our Head of Corporate Development from March 2009 to February 2013 where he led business development, strategy and program and alliance management functions. Prior to serving as our Head of Corporate Development, Mr. Raythatha joined Red Abbey Venture Partners, LLC in 2005 and served as a Kauffman Fellow from 2005 to 2007 principal from 2007 to 2009 and venture partner in 2009. Prior to Red Abbey Venture Partners, Mr. Raythatha worked at Biogen Inc. from 1999 to 2003 in a variety of business development, commercial, and program management roles. He earned an M.B.A. from Columbia University and a B.A. in biochemistry and economics from Rutgers University.- Jigar Raythatha自2017年3月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。Raythatha先生曾于2012年12月至2017年2月担任生物技术公司JounceTherapeutics，Inc.的首席商务官，在那里他帮助将公司从成立之初建立为公开交易的研究与开发组织。此前，他曾担任我们的公司发展主管（从2009年3月到2013年2月），在那里他曾领导业务发展、战略、计划和联盟管理职能。在担任公司发展主管之前，Raythatha先生于2005年加入Red Abbey Venture Partners，LLC，并于2005年至2007年担任考夫曼研究员，于2007年至2009年担任负责人，并于2009年担任风险合伙人。加入Red Abbey Venture Partners之前，Raythatha从1999年到2003年在BiogenInc.担任多个业务开发、商业和项目管理职位。他在哥伦比亚大学（Columbia University）获得工商管理硕士学位，在罗格斯大学（Rutgers University）获得生物化学和经济学学士学位。
- Jigar Raythatha has served as our President and Chief Executive Officer and as a member of our Board of Directors since March 2017. Mr. Raythatha previously served as Chief Business Officer of Jounce Therapeutics, Inc., a biotechnology company, from December 2012 to February 2017 where he helped build the company from its inception to a publicly traded research and development organization. Previously, he served as our Head of Corporate Development from March 2009 to February 2013 where he led business development, strategy and program and alliance management functions. Prior to serving as our Head of Corporate Development, Mr. Raythatha joined Red Abbey Venture Partners, LLC in 2005 and served as a Kauffman Fellow from 2005 to 2007 principal from 2007 to 2009 and venture partner in 2009. Prior to Red Abbey Venture Partners, Mr. Raythatha worked at Biogen Inc. from 1999 to 2003 in a variety of business development, commercial, and program management roles. He earned an M.B.A. from Columbia University and a B.A. in biochemistry and economics from Rutgers University.
- Patrick Trojer
Patrick Trojer自2017年6月起担任我们的高级副总裁，EZH2专营权和转化科学主管。Trojer博士于2008年加入我们，担任创始科学家。Trojer博士曾担任公司多个职位，包括Vice President，2015年10月至2017年6月担任研究主管，2014年10月至2015年10月担任执行董事，2014年3月至2014年10月担任高级董事，2012年3月至2014年10月担任生物学主管，从2010年到2012年3月担任生物学主管，从2009年到2010年担任高级科学家，从2008年到2009年担任科学家。Trojer博士在纽约大学医学院（NYU Medical School）完成博士后学习，在此之前，他在奥地利因斯布鲁克的利奥波德·弗兰岑大学（Leopold Franzens University）获得蛋白质生物化学与分子生物学博士学位和微生物学硕士学位。
Patrick Trojer has served as our Chief Scientific Officer since November 2018. Prior to that, Dr. Trojer served as our Senior Vice President, EZH2 franchise and Head of Translational Sciences since June 2017. Dr. Trojer joined us as a founding scientist in 2008. Dr. Trojer has served in various positions at our company, including as Vice President, Head of Research from October 2015 to June 2017 Executive Director, Head of Biology from October 2014 to October 2015 Senior Director, Head of Biology from March 2012 to October 2014 Director, Head of Biology from 2010 to March 2012 Senior Scientist from 2009 to 2010 and Scientist from 2008 to 2009. Dr. Trojer completed his postdoctoral studies at NYU Medical School, prior to which he received a Ph.D. in protein biochemistry and molecular biology and an M.S. in microbiology from the Leopold Franzens University in Innsbruck, Austria.- Patrick Trojer自2017年6月起担任我们的高级副总裁，EZH2专营权和转化科学主管。Trojer博士于2008年加入我们，担任创始科学家。Trojer博士曾担任公司多个职位，包括Vice President，2015年10月至2017年6月担任研究主管，2014年10月至2015年10月担任执行董事，2014年3月至2014年10月担任高级董事，2012年3月至2014年10月担任生物学主管，从2010年到2012年3月担任生物学主管，从2009年到2010年担任高级科学家，从2008年到2009年担任科学家。Trojer博士在纽约大学医学院（NYU Medical School）完成博士后学习，在此之前，他在奥地利因斯布鲁克的利奥波德·弗兰岑大学（Leopold Franzens University）获得蛋白质生物化学与分子生物学博士学位和微生物学硕士学位。
- Patrick Trojer has served as our Chief Scientific Officer since November 2018. Prior to that, Dr. Trojer served as our Senior Vice President, EZH2 franchise and Head of Translational Sciences since June 2017. Dr. Trojer joined us as a founding scientist in 2008. Dr. Trojer has served in various positions at our company, including as Vice President, Head of Research from October 2015 to June 2017 Executive Director, Head of Biology from October 2014 to October 2015 Senior Director, Head of Biology from March 2012 to October 2014 Director, Head of Biology from 2010 to March 2012 Senior Scientist from 2009 to 2010 and Scientist from 2008 to 2009. Dr. Trojer completed his postdoctoral studies at NYU Medical School, prior to which he received a Ph.D. in protein biochemistry and molecular biology and an M.S. in microbiology from the Leopold Franzens University in Innsbruck, Austria.
- Jeffrey Humphrey
Jeffrey Humphrey自2020年6月起担任我们的首席医疗官。在加入我们之前，Humphrey博士于2012年4月至2020年6月在制药和生物技术公司Kyowa Kirin Co.Ltd.的分支机构担任过各种职务。在Kyowa Kirin，他于2019年8月至2020年6月担任首席开发官，于2013年4月至2019年8月担任Kyowa Kirin Pharmaceutical Development，Inc.的总裁兼首席医疗官，并担任Kyowa Hakko Kirin Pharma药物开发高级副总裁，Inc.从2012年4月到2013年3月。他曾在辉瑞，拜耳和百时美施贵宝担任早期和晚期药物开发和医疗事务的高级管理职位。Humphrey博士拥有哈佛大学工商管理硕士学位和凯斯西储大学医学院医学博士学位。
Jeffrey Humphrey has served as our Chief Medical Officer since June 2020. Prior to joining us, Dr. Humphrey served in various positions at affiliates of Kyowa Kirin Co. Ltd. “Kyowa Kirin, a pharmaceutical and biotechnology company, from April 2012 to June 2020. At Kyowa Kirin, he served as Chief Development Officer from August 2019 to June 2020 as President and Chief Medical Officer of Kyowa Kirin Pharmaceutical Development, Inc. from April 2013 to August 2019 and as Senior Vice President, Drug Development of Kyowa Hakko Kirin Pharma, Inc. from April 2012 to March 2013. He previously served in senior management positions for early and late drug development and medical affairs at Pfizer, Bayer, and Bristol Myers Squibb. Dr. Humphrey holds a A.B. from Harvard University and an M.D. from Case Western Reserve University School of Medicine.- Jeffrey Humphrey自2020年6月起担任我们的首席医疗官。在加入我们之前，Humphrey博士于2012年4月至2020年6月在制药和生物技术公司Kyowa Kirin Co.Ltd.的分支机构担任过各种职务。在Kyowa Kirin，他于2019年8月至2020年6月担任首席开发官，于2013年4月至2019年8月担任Kyowa Kirin Pharmaceutical Development，Inc.的总裁兼首席医疗官，并担任Kyowa Hakko Kirin Pharma药物开发高级副总裁，Inc.从2012年4月到2013年3月。他曾在辉瑞，拜耳和百时美施贵宝担任早期和晚期药物开发和医疗事务的高级管理职位。Humphrey博士拥有哈佛大学工商管理硕士学位和凯斯西储大学医学院医学博士学位。
- Jeffrey Humphrey has served as our Chief Medical Officer since June 2020. Prior to joining us, Dr. Humphrey served in various positions at affiliates of Kyowa Kirin Co. Ltd. “Kyowa Kirin, a pharmaceutical and biotechnology company, from April 2012 to June 2020. At Kyowa Kirin, he served as Chief Development Officer from August 2019 to June 2020 as President and Chief Medical Officer of Kyowa Kirin Pharmaceutical Development, Inc. from April 2013 to August 2019 and as Senior Vice President, Drug Development of Kyowa Hakko Kirin Pharma, Inc. from April 2012 to March 2013. He previously served in senior management positions for early and late drug development and medical affairs at Pfizer, Bayer, and Bristol Myers Squibb. Dr. Humphrey holds a A.B. from Harvard University and an M.D. from Case Western Reserve University School of Medicine.
- Karen Valentine
Karen Valentine自2018年7月起担任我们的首席法律官and General Counsel。在加入我们之前，Valentine女士于2015年9月至2018年7月担任AgenusInc.（一家上市的免疫肿瘤公司）的首席法律官and General Counsel，并于2008年1月至2015年9月担任AgenusInc.的副总裁and General Counsel。在2004年加入AgenusInc.之前，Valentine女士是Palmer&Dodge LLP（现为Locke Lorde LLP）生物技术实践的合伙人。瓦伦丁女士目前是公司法律顾问协会东北分会的董事会成员。Valentine女士拥有科尔盖特大学神经科学学士学位，并获得了波士顿大学法学院的法学博士学位。
Karen Valentine has served as our Chief Legal Officer and General Counsel since July 2018. Prior to joining us, Ms. Valentine served as the Chief Legal Officer and General Counsel of Agenus Inc., a publicly traded immune-oncology company from September 2015 to July 2018 and served as Vice President and General Counsel of Agenus Inc. from January 2008 to September 2015. Prior to joining Agenus Inc. in 2004 Ms. Valentine was an associate in the biotechnology practice of Palmer & Dodge LLP now Locke Lorde LLP. Ms. Valentine is currently a member of the board of directors of the Northeast Chapter of the Association of Corporate Counsel. Ms. Valentine holds a B.S. in neuroscience from Colgate University and received her J.D. from Boston University School of Law.- Karen Valentine自2018年7月起担任我们的首席法律官and General Counsel。在加入我们之前，Valentine女士于2015年9月至2018年7月担任AgenusInc.（一家上市的免疫肿瘤公司）的首席法律官and General Counsel，并于2008年1月至2015年9月担任AgenusInc.的副总裁and General Counsel。在2004年加入AgenusInc.之前，Valentine女士是Palmer&Dodge LLP（现为Locke Lorde LLP）生物技术实践的合伙人。瓦伦丁女士目前是公司法律顾问协会东北分会的董事会成员。Valentine女士拥有科尔盖特大学神经科学学士学位，并获得了波士顿大学法学院的法学博士学位。
- Karen Valentine has served as our Chief Legal Officer and General Counsel since July 2018. Prior to joining us, Ms. Valentine served as the Chief Legal Officer and General Counsel of Agenus Inc., a publicly traded immune-oncology company from September 2015 to July 2018 and served as Vice President and General Counsel of Agenus Inc. from January 2008 to September 2015. Prior to joining Agenus Inc. in 2004 Ms. Valentine was an associate in the biotechnology practice of Palmer & Dodge LLP now Locke Lorde LLP. Ms. Valentine is currently a member of the board of directors of the Northeast Chapter of the Association of Corporate Counsel. Ms. Valentine holds a B.S. in neuroscience from Colgate University and received her J.D. from Boston University School of Law.